Evidence map›Paper›PMID 42625275›Full record

Observational studyDiabetes/metabolism research and reviews2026

Predictive Value for Preeclampsia of sFlt-1:PlGF Ratio in Pregnancy Complicated by Gestational Diabetes.

Fabrizia Citro, Cristina Bianchi, Francesca Nicolì, Michele Aragona, Giovanni De Gennaro, Stefano Del Prato, Giuseppe Penno, Alessandra Bertolotto, Lorella Battini

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Diabetes/metabolism research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04877119 (Predictive Value for Preeclampsia of the sFlt-1), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04877119 unknown statusnot on this map

Predictive Value for Preeclampsia of the sFlt-1:PlGF (Soluble Foms-like Tyrosine Kinase 1/Placental Growth Factor) Ratio in Pregnancy Complicated by Gestational Diabetes: The PREDICTION (PREeclampsia in DIabetiC gestaTION) Study

Typeobservational_patient_registrySponsorAzienda Ospedaliero, Universitaria PisanaRan2019 to 2022Enrolled500ConditionsGestational Diabetes, Gestational Hypertension, Pre-Eclampsia
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fabrizia CitroDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0009-0000-1673-2327
Cristina BianchiDepartment of Endocrine-Metabolic and Transplant Surgery and Medicine, University Hospital of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0003-2799-2380
Francesca NicolìEndocrine Diseases and Regional Diabetes Mellitus Center, ASST Bergamo Ovest, Treviglio, Italy.
Michele AragonaDepartment of Endocrine-Metabolic and Transplant Surgery and Medicine, University Hospital of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0002-5982-7913
Giovanni De GennaroMetabolic Diseases and Diabetes Unit, Misericordia Hospital, Grosseto, Italy.ORCID https://orcid.org/0009-0004-8696-2995
Stefano Del PratoInterdisciplinary Research Center 'Health Science,' Sant'Anna School of Advanced Studies, Pisa, Italy.ORCID https://orcid.org/0000-0002-5388-0270
Giuseppe PennoDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Alessandra BertolottoDepartment of Endocrine-Metabolic and Transplant Surgery and Medicine, University Hospital of Pisa, Pisa, Italy.
Lorella BattiniMaternal-Infant Department, University Hospital of Pisa, Pisa, Italy.

Funding

Roche Diagnostics
6 · The paper itself

Abstract

BACKGROUND AND

aimsGestational diabetes (GDM) and preeclampsia (PE) are major complications of pregnancy. The ratio of soluble Fms-like tyrosine kinase 1 to placental growth factor (sFlt-1/PlGF) may predict the short-term absence of PE in pregnant women with clinically suspected PE. The aim of this study was to determine the role of placental angiogenic factors in predicting PE risk in women with pregnancies complicated by GDM. MATERIALS AND

methodsIn this prospective observational study, pregnant women were enrolled at the time of screening for GDM. sFlt-1 and PlGF were measured at 24-28, 28-32 and 35-37 weeks of gestation. Univariate and multivariate analysis were used to investigate risk factors for PE.

resultsOf 398 women, 213 (53.5%) had GDM and 18 (5%) developed PE (67% with GDM). GDM women developing PE had significantly lower levels of PlGF at 24-28, 28-32 and 35-37 gestational weeks, and higher sFlt1 and sFlt1/PlGF at 28-32 and 35-37 gestational weeks compared with GDM women without PE. On a multivariate analysis, PlGF and sFlt1/PlGF were associated with PE, regardless of other clinical data. A sFlt1/PlGF ratio > 38 at 28-32 gestational weeks identified GDM women at risk of developing PE within the ensuing 4 weeks, with 100% sensitivity and good specificity.

conclusionIn women with GDM, the sFlt1/PlGF ratio can identify those at higher risk of PE.

trial registrationNCT04877119: 2021-04-29.

Indexed as

BiomarkersDiabetes, GestationalPlacenta Growth FactorPre-EclampsiaVascular Endothelial Growth Factor Receptor-1AdultFemaleFollow-Up StudiesHumansPredictive Value of TestsPregnancyPrognosisProspective StudiesRisk FactorsBiomarkersFLT1 protein, humanPGF protein, humanPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1gestational diabeteshypertensive disordersplacental angiogenic factorspredictive risk factorspreeclampsiapregnancysFlt1/PlGF ratio

Identifiers

PMID42625275
PMCPMC13494058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.